Positioning of Depemokimab in Uncontrolled Severe Asthma.

Authors

Juan Carlos Miralles-López, Ismael García-Moguel, Alicia Habernau-Mena, Manuel Jorge Rial-Prado, Ana Montoro-Ferrer, Darío Antolín-Amérigo

Published in

Journal of investigational allergology & clinical immunology. Pages 0. Oct 19, 2026. Epub Oct 19, 2026.

Abstract

Asthma is a chronic inflammatory disease of the airways affecting more than 300 million people worldwide. It is estimated that between 3% and 10% have severe asthma. Depemokimab is the first ultra-long-acting anti-IL-5 monoclonal antibody developed for type 2 respiratory disease, enabling administration every 26 weeks. It produces rapid and sustained reductions in blood eosinophil counts. This twice-yearly regimen markedly reduces injection frequency and may lessen treatment burden. In the replicate phase 3 SWIFT-1 and SWIFT-2 trials, depemokimab reduced the pooled annualized rate of clinically significant exacerbations by 54% and exacerbations requiring hospitalization or emergency department care by 72% compared with placebo in patients aged 12 years or older with severe eosinophilic asthma. In chronic rhinosinusitis with nasal polyps (CRSwNP), depemokimab was evaluated in the replicate phase 3 ANCHOR-1 and ANCHOR-2 trials. Both coprimary endpoints were met, and these studies provide evidence that twice-yearly depemokimab reduces the endoscopic nasal polyp score and improves nasal obstruction over 52 weeks in inadequately controlled CRSwNP. Depemokimab is approved for both severe asthma with type 2 inflammation and severe CRSwNP, making it a therapeutic option when both conditions coexist. Based on currently available evidence, depemokimab represents an additional option for patients with severe eosinophilic asthma in whom prevention of exacerbation is a major therapeutic goal. The twice-yearly dosing schedule may also be relevant when reducing treatment burden is a patient priority, although the effect of this reduction on adherence and persistence remains to be proved.

PMID:
42895519
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.